Report Company Directory

Cytokinetics Incorporated

• Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM) by GlobeNewsWire
• Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms by GlobeNewsWire
• Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) by GlobeNewsWire
• US Pharmaceuticals & Biotechnology "Day 2 takeaways: JAZZ EXEL CORT CYTK..." by UBS AG
• US Pharmaceuticals & Biotechnology "JAZZ stat change a positive. CYTK..." by UBS AG
• US Biotechnology "Questions: INSM NBIX INCY EXEL CORT CYTK AXSM IMVT..." by UBS AG
• Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference by GlobeNewsWire
• Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms by GlobeNewsWire
• US Pharmaceuticals "SMID-Biotech: NBIX, EXEL, BIIB, IMVT, DNLI, CYTK -..." by UBS AG
• Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy by GlobeNewsWire

CYTOMED THERAPEUTICS LIMITED

• CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress by GlobeNewsWire
• CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital by GlobeNewsWire
• CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia by GlobeNewsWire
• CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India by GlobeNewsWire
• CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy by GlobeNewsWire
• CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95% by GlobeNewsWire
• CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets by GlobeNewsWire
• CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia  by GlobeNewsWire
• Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition by GlobeNewsWire
• CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program by GlobeNewsWire

CytomX Therapeutics Inc.

• CytomX Therapeutics to Present at Upcoming February Conferences by GlobeNewsWire
• Wedbush Morning Call - Feb 02 2026 7:03AM by Wedbush
• The Wedbush Monthly Check-Up: February 2026 by Wedbush
• 2026 Preview; Varseta-M Data on the Horizon by Wedbush
• CytomX Therapeutics Announces Business Update and Company Milestones for 2026 by GlobeNewsWire
• The Wedbush Monthly Check-Up: December 2025 by Wedbush
• CytomX Therapeutics to Present at Upcoming December Investor Conferences by GlobeNewsWire
• CytomX Therapeutics to Present at the Jefferies London Healthcare Conference by GlobeNewsWire
• Cytomx Therapeutics Inc: 1 director by SmartInsider
• SITC 2025 Roundup for Covered Companies by Wedbush

Cytori Therapeutics

• Cytori Strengthens Global Intellectual Property Portfolio with Key Patents by BusinessWire
• Cytori Granted FDA Orphan Drug Designation for ECCS-50 in Scleroderma by BusinessWire
• Cytori Reports Third Quarter 2016 Business and Financial Results by BusinessWire
• Cytori to Present Data in Two Distinct Models of Impaired Wound Healing by BusinessWire
• Cytori to Webcast Third Quarter Financial Results on November 9 by BusinessWire
• Cytori Presents Scleroderma Clinical Trial Data at the 2016 American College of Rheumatology Annual Meeting by BusinessWire
• Cytori Publication on Cytori Cell Therapy for Combined Radiation and Thermal Injury by BusinessWire
• BARDA Increases Contract Option with Cytori to Advance Countermeasure Clinical Trial by BusinessWire
• QuickView: Scleroderma therapy efficacy maintained by Edison Investment Research
• QuickView: Focused on clinical cell therapies by Edison Investment Research

Cytori Therapeutics